| |
Boehringer Ingelheim HCV Drug Development Program
|
| |
| |
Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials - (08/29/13)
Faldaprevir and Deleobuvir for HCV Genotype 1 Infection - (08/19/13) The New England Journal of Medicine
august 15, 2013
DDW: HIV COINFECTION; An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, BI 207127, and Ribavirin in the SOUND-C2 Study - (05/20/13)
EASL: FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS - (04/27/13)
Clinical Pharmacology Workshop at EASL April 2013: Boehringer Ingelheim J. Kort Pres.
APASL: INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR (BI 207127) AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV-GT1B - (06/10/13)
SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 http://www.natap.org/2012/EASL/EASL_38.htm
APASL: FALDAPREVIR PLUS PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAïVE PATIENTS: SUBANALYSIS OF PATIENTS FROM JAPAN, TAIWAN AND SOUTH KOREA - (06/09/13)
Boehringer Ingelheim's investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia - press release, link to presentation - (06/23/13)
BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C http://www.natap.org/2009/AASLD/AASLD_10.htm
4 week therapy with the non-nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon alfa2A and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients http://www.natap.org/2010/EASL/EASL_34.htm
APASL: Boehringer Ingelheim's investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia - press release, link to presentation - (06/23/13)
AASLD/2012: Boehringer Ingelheim's interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase II study including patients with advanced liver disease - (11/14/12)
AASLD/2012: INTERFERON (IFN)-FREE COMBINATION TREATMENT WITH THE HCV NS3/4A PROTEASE INHIBITOR FALDAPREVIR (BI 201335) AND THE NON-NUCLEOSIDE NS5B INHIBITOR BI 207127 ± RIBAVIRIN: FINAL RESULTS OF SOUND-C2 AND PREDICTORS OF RESPONSE - (11/14/12)
AASLD/2012: EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF FALDAPREVIR (BI 201335) + BI 207127 ± RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH HCV GT-1 AND COMPENSATED LIVER CIRRHOSIS: RESULTS FROM THE SOUND-C2 STUDY - (11/14/12)
Study Results For PPI668 NS5A, BI335 protease, BI127 non-nuc polymerase - new collaboration between Presidio & Boerhinger Ingelheim.......http://www.natap.org/2013/HCV/031513_01.htm
EASL: FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS - (04/27/13)
CROI: STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13)
CROI: Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13)
CROI: Boerhinger Ingelheim Announes Interim Results Evaluating Virologic Response Rates in HCV/HIV Coinfected Patients Treated with HCV Protease BI201335, and Drug Drug Interaction Studies with HIV ARTs - (03/04/13)
OVERALL BI HCV DRUG DEVELOPMENT REPORT including mono infection data for Faldaprevir & non-nuc Deleobuvir
Boehringer Ingelheim HCV R&D Mono and HIV Coinfection: Faldaprevir, Non-nuc Deleobuvir (BI127) - Mono- and HCV/HIV Coinfection, NS5A PPI-668 - (08/16/13)
|
|
| |
| |
|
|
|
